Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

HROW - Harrow Inc


IEX Last Trade
40.41
1.150   2.846%

Share volume: 946,719
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$39.26
1.15
2.93%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
13%
Profitability 1%
Dept financing 19%
Liquidity 68%
Performance 10%
Company vs Stock growth
vs
Performance
5 Days
-5.25%
1 Month
68.44%
3 Months
126.79%
6 Months
269.84%
1 Year
156.08%
2 Year
366.13%
Key data
Stock price
$40.41
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$7.60 - $44.80
52 WEEK CHANGE
$1.61
MARKET CAP 
1.436 B
YIELD 
N/A
SHARES OUTSTANDING 
35.483 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
BETA 
1.69
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$817,454
AVERAGE 30 VOLUME 
$935,781
Company detail
CEO:
Region: US
Website: harrowinc.com
Employees: 22
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas

Recent news